NorthWest Biotherapeutics Inc (NWBO)

[Basin Street Blues]

I think Juno & Kite set the benchmark for what comparable
revenue streams would be worth if we sell L.

So sell L for $8bn or maybe a lot more as Large Pharma will now know
there`s no difference between L and D other than the indications they`ve
been trialled in, but that then leaves a dilemma as to the Net Present Value of all of D`s targeted cancers if indeed by definition L can do the same job .

So..if L & D are the same and the intrinsic value for L is lets say
$8bn add the NPV of the stage 1/2 trials of D for another $8bn we could well be looking at $16bn, or $16pps

Before anyone says L & D are not the same, I was told that DIRECTLY from an officer of the company so dont bother.